InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Application for quotation of securities - OPT 11 Mar 2025 1:17PM $0.643 $0.013 fallen by 97.98%
$18 Opthea Announces Phase 2b Wet AMD Publication 3 Mar 2025 8:22AM $0.960 $0.013 fallen by 98.65%
$18 Opthea Reports Half Year Results and Business Updates 28 Feb 2025 8:22AM $0.935 $0.013 fallen by 98.61%
$18 Opthea Half Year Financial Report - Appendix 4D 28 Feb 2025 8:21AM $0.935 $0.013 fallen by 98.61%
$18 Opthea Completes Drug Product PPQ Campaign 26 Feb 2025 8:06AM $0.960 $0.013 fallen by 98.65%
$18 Application for quotation of securities - OPT 21 Feb 2025 4:53PM $1.010 $0.013 fallen by 98.71%
$18 Application for quotation of securities - OPT 21 Feb 2025 4:52PM $1.010 $0.013 fallen by 98.71%
$18 Application for quotation of securities - OPT 19 Feb 2025 8:33AM $1.000 $0.013 fallen by 98.70%
$18 Opthea Completes COAST Final Week 52 Patient Visit 18 Feb 2025 8:18AM $1.020 $0.013 fallen by 98.73%
$18 Application for quotation of securities - OPT 17 Feb 2025 4:12PM $1.020 $0.013 fallen by 98.73%
$18 Notification of cessation of securities - OPT 11 Feb 2025 6:53PM $1.050 $0.013 fallen by 98.76%
$18 Application for quotation of securities - OPT 11 Feb 2025 6:51PM $1.050 $0.013 fallen by 98.76%
$18 Opthea to Present at Oppenheimer Healthcare Conference 7 Feb 2025 8:31AM $1.155 $0.013 fallen by 98.87%
$18 Opthea Wet AMD Data Featured at Macula Society Meeting 6 Feb 2025 9:14AM $1.100 $0.013 fallen by 98.82%
$18 Change in substantial holding 4 Feb 2025 4:56PM $1.080 $0.013 fallen by 98.80%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2025 10:43AM $1.070 $0.013 fallen by 98.79%
$18 Application for quotation of securities - OPT 30 Jan 2025 9:46AM $1.030 $0.013 fallen by 98.74%
$18 Opthea Investor Day 29 Jan 2025 8:14AM $1.030 $0.013 fallen by 98.74%
$18 Opthea's Corporate Presentation - Jan 2025 14 Jan 2025 8:15AM $0.750 $0.013 fallen by 98.27%
$18 Opthea to Host Investor Days in New York and Australia 8 Jan 2025 9:18AM $0.795 $0.013 fallen by 98.36%
$18 Opthea Announces Publication in Diabetic Macular Edema 7 Jan 2025 8:22AM $0.740 $0.013 fallen by 98.24%
$18 Application for quotation of securities - OPT 24 Dec 2024 1:57PM $0.760 $0.013 fallen by 98.29%
$18 Notification regarding unquoted securities - OPT 24 Dec 2024 1:43PM $0.755 $0.013 fallen by 98.28%
$18 Notification of cessation of securities - OPT 24 Dec 2024 1:36PM $0.765 $0.013 fallen by 98.30%
$18 Notification regarding unquoted securities - OPT 24 Dec 2024 1:33PM $0.765 $0.013 fallen by 98.30%

76 - 100 of 733 results

Page 4 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.